ID: MRFR/MED/4708-CR | August 2019 | Region: Global | 157 pages
Prefilled syringes market is expected to reach around USD 11479.332 Million by 2027 from the current market of USD 11.72 billion. The CAGR is anticipated to be approx. USD 11.72% in the forecast period. The high demand in the prefilled syringes market is mostly attributed to some major things such as the advancement of technologies, the pervasiveness of chronic diseases, needlestick or other government regulations, and self-injecting or adoption devices.
The awareness of prefilled syringes benefits is increasing with the support of the growing number of biosimilars and biologics in the pharmaceuticals market among healthcare professionals and patients. In the next 6 years, safety prefilled syringes have great potential to be in the top position among prefilled syringes market players by being the fastest expanding segment.
The growth of this prefilled syringes market can be accredited for the healthcare expenditure along with the high autoimmune disorder prevalence, self-mediations, and others. According to AARDA (American Autoimmune Related Diseases Association Inc), more than 50 million patients are suffering from this disorder only in America. During the period of forecast, the increase of product launches from key players and the growing adoption of products by medical professionals will boost the prefilled syringes market.
The market of prefilled syringes had a very huge impact due to the COVID 19 pandemic. It has a short-term impact on the supply chain, drug manufacturing process as well which affected the market. To reduce the spread of COVID 19 and follow the regulations, the HCPs have adapted plenty of new ways to deliver the care. The demand for prefilled syringes increased a lot more than the glass ampoules to reduce needle-stick injury risks.
The manufacturers are increasing their capacity of production to meet the demand for COVID 19 vaccine. For example, the US government has ordered more than 100 million prefilled syringes by signing a deal of around $138 million with manufacturers to have huge quality of vaccine ready by the middle of 2021. One of which includes telemedicine that helps to keep the continuation of appointments. Different apps have been introduced that help with chronic conditions to get self-support.
The glucose monitoring devices are supporting diabetes patients. The contribution of the pharmacist community is going to be essential to promote medication and take care of chronic conditions during and after the COVID 19 pandemic. It is necessary to lighten the burden of already strained medical systems. Overall, the prefilled syringes market had a positive impact due to COVID 19 pandemic and more than 10.6% growth from 10.3.
The demand for injectable delivery innovations and biological drugs is increasing rapidly. They are likely to drive the growth of the prefilled syringes market in the forecast period. Diseases like autoimmune disorders, cancer, and others have a limited option of treatment available. As the leading players of the market target these diseases, the biological drugs have managed to get their attention. For example, the W. L. Gore & Associates Inc introduced the Gore Imroject Plunger for prefilled syringes on 19th March 2019, which is a silicon-sensitive biologics solution.
Also, the number of cancer patients is expected to rise to 22 billion by 2027 in the US that will increase the biologics demand. With chronic diseases, the demand for self-injection devices is increasing. The rise in number is expected to cross more than 550 million by 2027 among diabetes patients. There is a high chance of increasing the autoimmune disease cases as more than 8 million patients had auto-antibodies present in their blood molecules in the US that elevate the risk of autoimmune disease development.
Many countries are suffering from insufficient funds for healthcare, which is affecting the health status of people. In most places of South Asia and Africa, more than 400 million people are unable to receive healthcare services according to the World Bank. Based on the report of the Geneva Association, the increase in GDP in the last two decades is expected to be more than 8 trillion per year, which is caused by the advancement of treatment options, medical treatment cost, and others. By 2027, global spending on health will get a huge boost with an increased rate of 5.3% per year on average.
While loading medication from vials, the chance of toxic exposure is very high, which is reduced a lot by using the prefilled syringes. They offer great safety for patients and reduce the risk of needlestick injuries. However, the use of bare prefilled syringes without safety systems can lead to needle stick injury as well. More than 1,000,000 injuries occurred only in Europe in 2019.
They have a high chance of transferring infections like HCV, HIV, and others. The manufacturing process of safety features is much more expensive which is creating a major concern. However, the industry is expected to develop more safety prefilled syringes in the upcoming years.
The main challenge faced by the prefilled syringes is the cost of the disposable syringe is lower. The manufacturing process of prefilled syringe makes it expensive. Also, the oral medicines are most accepted by the parties as it is less painful and convenient. The use of insulins that are injectable is getting limited like Medtronic’s Veo insulin, Pfizer’s Exubera, and others. Inhalable insulin has affected the market growth of injectables as they are pain-free. In the forecast period, the treatments like oral anemia are expected to have an adverse effect on injectable technology growth.
With the increasing number of patients with chronic diseases and self-injective devices, prefilled syringes are becoming very attractive for healthcare professionals and biotechnology products. The prefilled syringes market is expected to reach more than 9 billion USD by the end of 2027. The compound annual growth rate (CAGR) is projected to be around 9% in the period of forecast.
The prefilled syringes market is very valuable and highly necessary for the growth of the overall healthcare industry. With increasing chronic diseases, the use of prefilled syringes is expected to increase a lot in the forecast period. The process of making safety prefilled syringes will also help to get a better market grasp than the disposable syringes by offering a lower price. It will also ensure safety from transferable diseases like HCV and HIV.
Glass Segment - The market of prefilled syringes is divided into plastic and class based on material. Glass segment holds the largest share in the market among them. The strong barrier properties of glass make it the most preferred choice by the manufacturer. However, there are some concerts associated with glass such as breakage, drugs reaction with glass ions, and others.
Plastic Segment - Plastic is expected to be used more in the forecast period by the manufacturers. Technological innovations are offering many advantages of plastic syringes over the glass. The key players in the market are involved with the development of plastic syringes.
The market is segmented into components, syringe sets, and accessories based on the product. Among them, the syringe set is capturing a major portion of the market. For rising demand for self-injectable and effective delivery of drugs among patients is increasing the market share. In the forecast period, the accessories and components are expected to make a decent growth. The complete set is in much more demand compared to the independent components.
The market of prefilled syringes is geographically segmented in the Asia Pacific, North America, Europe, Middle East, and Latin America. However, the market is dominated by Europe with more than USD 1.93 billion in the year 2019. The factors that help to get a high demand in Europe include the use of biologics treatments on patients, technological advancement, and adaption of drugs or self-injection. North America is most likely to be the second-largest market of prefilled syringes among others.
Some of the leading players in this market with strong brand recognition and a wide range of offerings include SCHOTT AG, Gerresheimer AG, West Pharmaceutical Services, BD, and others. These companies are most likely to continue their dominance and generate very good revenue in the forthcoming years. The expanding market and entry of new companies making it globally recognizable. For example, Gerresheimer AG introduced the Gx RTF Clearject polymer needle syringe 2.25ml in September 2019 that expands the pre-fillable polymer syringes.
List of the Key Competitive Companies:
Customizable prefilled glass launched by SCHOTT AG pharmaceutical packaging company by India. The BioPure glass is very well known for offering the customizable option in prefilled staked-needle syringe. It is designed specially to keep the sensitive drugs very stable and make the treatments more convenient.
BD Intevia 1mL two-step disposable autoinjector introduced by Becton, Dickinson, and Company. This is a device with a robust platform to combine a prefillable syringe and autoinjector in one system.
The market of prefilled syringes provides different insights and information about the forecast. Some of these include restraints, drivers, regional analysis, competitive landscape, and challenges. Furthermore, it offers an analytical depiction of the prefilled syringes market investment opportunities, trends, and others. The information provided in the report is gathered from different secondary and primary sources.
|Market Size||USD USD 11479.332 Million|
|Forecast Units||Value (USD Billion)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Material, Type, Design, End User and Region|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||SCHOTT AG, BD, Gerresheimer AG, West Pharmaceutical Services Inc, AptarGroup, Inc., Helvoet Rubber & Plastic Technologies BV, Terumo Corporation, Nipro PharmaPackaging International,|
|Key Market Opportunities||Global spending on health will get a huge boost|
|Key Market Drivers||The demand for injectable delivery innovations and biological drugs is increasing rapidly|
Frequently Asked Questions (FAQ) :
Prefilled Syringes Market is predicted to touch USD USD 11479.332 Million by 2027.
Prefilled Syringes Market is projected to grow at a 9% CAGR between 2020-2027.
Europe is projected to dominate the Prefilled Syringes Market.
The top vendors in the market of the Prefilled Syringes are Weigao Group, Becton, Abbott, OMPI (A Stevanato Group Company), Baxter, Vetter Pharma International GmbH, West Pharmaceutical, Medtronic, Dickinson and Company, Nipro Corporation, TERUMO CORPORATION, Schott AG, Medtronic, and Gerresheimer AG, MicSafe Medical Group (China), Elcam Medical (Israel), Oval Medical Technologies (UK), YPSOMED (Switzerland), SHL Medical AG (Switzerland), Owen Mumford Ltd. (UK), Datwyler (Switzerland), Catalent, Nipro Corporation (Japan), MedXL (Canada), Ompi (Italy), and others.
The geographic region is expected to have substantial growth in the Asia Pacific more than 11.3% in the forecast period. The increasing demand for prefilled syringes is expected to grow due to treatments like high penetration, high prevalence of diabetes, self-administered, self-injection devices, diabetes, increasing aging population, and high patient population. There are some other regions available where the prefilled syringes are expected to have significant demand.
Like many other industries, the prefilled syringe market also had a deep impact on the COVID 19 pandemic. It has become a challenge for patients with chronic diseases like obstructive pulmonary disease, diabetes, hypertension, and others to have routine care. These are some of the most impacted diseases with the COVID 19 pandemic. Additionally, the healthcare resources are now focused on the COVID 19, which is expected to have a great disruption in the continuum of chronic disease care.